References 1 FDABremelanotide (Vyleesi) prescribing information dosing, indication (premenopausal HSDD), and use limitations
In 2024, West Virginia launched a pilot providing Wegovy to 1,000 state employees and dependents

Medications highlighted in the graphic include: Oral Wegovy - GLP-1 receptor agonist - ~13 to 17% estimated weight loss Wegovy 7.2 mg - Higher-dose injectable GLP-1 - ~20 to 21% estimated weight loss Orforglipron - Oral non-peptide GLP-1 agonist - ~11 to 15% estimated weight loss CagriSema - Amylin analog + GLP-1 agonist - ~20 to 23% estimated weight loss Retatrutide - Triple agonist (GIP, GLP-1, glucagon) - up to ~28 to 29% estimated weight loss Survodutide - Dual agonist (GLP-1, glucagon) - ~15 to 19% estimated weight loss MariTide - GIP antagonist + GLP-1 antibody-drug conjugate - ~18 to 20% estimated weight loss A few important notes for context: The percentages shown are trial-based estimates and vary by dose, duration, and analysis method Timelines reflect best estimates, not guarantees Real-world outcomes will depend on access, tolerability, and individualized care That said, the direction is clear

And so what we did is we looked at that and we wanted to see whether the GLP-1s affected that